Start free

Cue Biopharma, Inc. (CUE) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 14, 2026.

Filings shown
19
Open-market buys
0
Open-market sells
15

Counts cover the 19 most recent Form 4 filings Tradune holds for CUE (filed May 7 – Oct 14, 2026); the score below covers only the trailing 90 days (0 buys, 4 sells). SEC EDGAR Form 4 filings for CUE last checked Nov 21, 2026, 09:00 UTC; the latest CUE filing Tradune holds was filed Oct 14, 2026. This is not guaranteed to be the complete record — see CUE's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 5 filings Tradune holds for CUE filed Aug 28 – Oct 14, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

4 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
0 sales· 0 sh
checkbox disclosed
On filings with the box not checked
4 sales· 14,075 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Shao-Lee LinChief Executive Officer 0 2 — 11,087 −$305,490
Sumita RayChief Legal Compliance Officer 0 1 — 1,844 −$51,724
Michael Vincent MeluzioVP, Prin. Accounting Officer 0 1 — 1,144 −$32,089

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 4 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at CUE

No open-market insider purchases (Form 4 code P) were reported for CUE between May 7, 2026 and Oct 14, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Michael Vincent Meluzio VP, Prin. Accounting Officer · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,144 $28.05 47,817 −2.3% Oct 12, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Shao-Lee Lin Chief Executive Officer · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,087 $28.05 694,908 −0.2% Oct 12, 2026
Open-market sale 10b5-1 box not checked 10,000 $27.50 695,995 −1.4% Oct 12, 2026
Sumita Ray Chief Legal Compliance Officer · filed Oct 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,844 $28.05 116,701 −1.6% Oct 12, 2026
Pasha Sarraf amended Director · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 18,400 — 29,195 +170% Jul 9, 2026
Pamela Garzone amended Director · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 18,900 — 18,900 — Jul 9, 2026
Michael Vincent Meluzio VP, Prin. Accounting Officer · filed Aug 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,519 $29.37 53,070 −2.8% Aug 13, 2026
Option exercise 13,647 — 54,589 +33% Aug 13, 2026
Option exercise Common Stock 13,647 — — — Aug 13, 2026
Open-market sale 10b5-1 box not checked 3 $31.13 48,961 −0.0% Aug 13, 2026
Open-market sale 10b5-1 box not checked 4,106 $30.35 48,964 −7.7% Aug 13, 2026
Sumita Ray Chief Legal Compliance Officer · filed Aug 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Common Stock 18,196 — — — Aug 13, 2026
Open-market sale 10b5-1 box not checked 4 $31.13 118,545 −0.0% Aug 13, 2026
Open-market sale 10b5-1 box not checked 6,442 $30.35 118,549 −5.2% Aug 13, 2026
Option exercise 18,196 — 127,374 +17% Aug 13, 2026
Open-market sale 10b5-1 box not checked 2,383 $29.37 124,991 −1.9% Aug 13, 2026
Shao-Lee Lin Chief Executive Officer · filed Aug 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 2,375 $28.11 716,455 −0.3% Aug 13, 2026
Open-market sale 10b5-1 box not checked 10,460 $29.48 705,995 −1.5% Aug 13, 2026
Open-market sale 10b5-1 box not checked 5,423 $27.19 718,830 −0.7% Aug 13, 2026
Open-market sale 10b5-1 box not checked 5,775 $27.75 724,253 −0.8% Aug 12, 2026
Option exercise 109,179 — 764,253 +17% Aug 12, 2026
Open-market sale 10b5-1 box not checked 34,225 $26.99 730,028 −4.5% Aug 12, 2026
Option exercise Common Stock 109,179 — — — Aug 12, 2026
James M. Ahlers Chief Financial Officer · filed Aug 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 25,500 — 25,500 — Jul 30, 2026
Grant / award Stock Option (Right to Buy) 51,000 — — — Jul 30, 2026
Shao-Lee Lin amended Chief Executive Officer · filed Jul 30, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Common Stock Warrants (Right to Buy) 45,453 — — — Jun 1, 2026
Grant / award Pre-Funded Warrants (Right to Buy) 90,906 $11.00 — — Jun 1, 2026
Dominique Christian Borie Chief Medical Officer · filed Jul 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 31,500 — 31,500 — Jul 13, 2026
Grant / award Stock Option (Right to Buy) 63,000 — — — Jul 13, 2026
Michael Vincent Meluzio VP, Prin. Accounting Officer · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Common Stock 40,942 — — — Jul 9, 2026
Grant / award 40,942 — 40,942 — Jul 9, 2026
Viola Mong Meehan Director · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 21,800 — 21,800 — Jul 9, 2026
Daniel A. Camardo Director · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 21,800 — 21,800 — Jul 9, 2026
Shao-Lee Lin Chief Executive Officer · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Common Stock 327,537 — — — Jul 9, 2026
Grant / award 327,537 — 655,074 +100% Jul 9, 2026
Sumita Ray Chief Legal Compliance Officer · filed Jul 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Common Stock 54,589 — — — Jul 9, 2026
Grant / award 54,589 — 109,178 +100% Jul 9, 2026
Daniel A. Camardo Director · filed Jun 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,626 — — — May 30, 2026
Viola Mong Meehan Director · filed Jun 2, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 1,626 — — — May 30, 2026
Shao-Lee Lin CHIEF EXECUTIVE OFFICER · filed May 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 655,074 — — — May 3, 2026
Grant / award 327,537 — 327,537 — May 3, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to CUE's (Oct 14, 2026).

Frequently asked about CUE insider activity

How many insiders bought CUE stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of CUE shares were reported by Cue Biopharma, Inc. insiders between May 7, 2026 and Oct 14, 2026. The 19 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for CUE?

The most recent Form 4 on this page was filed by Sumita Ray (Chief Legal Compliance Officer) on Oct 14, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market CUE insider sale shown?

The largest open-market sale among the filings shown was 34,225 CUE shares at $26.99 (about $923,733) by Shao-Lee Lin (Chief Executive Officer) on Aug 12, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for CUE — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.